Relief Therapeutics Valuation Report "Play ACE!"

Tuesday, November 29, 2022 @ 12:00 am

Relief and NRx settled their litigation with Relief regaining all NRx rights to RLF-100. Near-term upside should be boosted by the US launches of PKU GOLIKE and ACER-001. Future upside comes from the diversified pipeline, including RLF-100 in rare lung disease, RLF-OD032 in PKU and RLF-TD011 in EB.

Key catalysts:

1. Closing definitive settlement agreements with NRx (mid-December 2022)
2. ACER-001 PDUFA date in urea cycle disorders (15 January 2023)
3. US launch of ACER-001 in UCDs (early 2023)

Relief Valuation Report "Play ACE!"

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Pharvaris' strategic priorities in 2025

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026 Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026 Study initiation of deucrictibant for the treatment of acquired
January 13, 2025

Sophia Genetics: ISO certifications for information security and privacy protection

Company reaffirms its commitment to information security and data protection in healthcare technology
January 9, 2025

Cytosurge: Strategic leadership transition

Cytosurge AG announces a leadership transition effective January 1, 2025. Co-founder Pascal Behr steps down as CEO after 12 years to join the Board as Delegate. Simon Egli, former Chief Commercial Officer, becomes CEO to lead the next growth phase. Under Behr, Cytosurge achieved milestones like 140+ FluidFM systems installed and 150+ publications. Egli, a biotech veteran, aims to advance innovatio
January 9, 2025

LimmaTech awarded FDA fast track designation for vaccine against Staphylococcus aureus

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LimmaTech’s multivalent toxoid vaccine candidate, LBT-SA7, designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen, Staphylococcus a
December 19, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024